Aclarion, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aclarion, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.7K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $45.7K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $75.4K | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $60.4K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $60.3K | Jun 12, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.8K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($38.9K) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($324) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($4.9K) | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | ($10.1K) | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | ($11.3K) | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | ($8.9K) | Jun 12, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.23M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($6.99M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($4.91M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($7.07M) | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | ($6.12M) | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | ($4.49M) | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | ($4.95M) | Jun 12, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.05M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($5.51M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($4.88M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($5.56M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.95M) | Jun 12, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $888.8K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $873.3K | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $1.07M | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | $849.0K | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | $558.0K | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | $787.9K | Jun 12, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.16M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($5.27M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($3.65M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($4.95M) | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | ($3.81M) | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | ($2.72M) | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | ($2.40M) | Jun 12, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.5K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $5.1K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Apr 9, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.67M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.12M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.46M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $2.91M | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | $4.10M | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | $5.62M | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | $1.89M | Jun 12, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $837.3K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.15M | Mar 18, 2026 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.84M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $970.1K | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($728.0K) | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $2.23M | Apr 9, 2025 |
| FY2022 | Sep 30, 2022 | $2.93M | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | $4.24M | Jun 12, 2023 |
| FY2023 | Dec 31, 2021 | ($12.83M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($7.08M) | Jun 12, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.50M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($51.26M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($44.28M) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($39.37M) | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | ($38.43M) | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | ($36.79M) | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | ($31.89M) | Jun 12, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.02M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $453.7K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $1.47M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $432.5K | Jun 12, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (7,478) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (79,782) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | (19) | Mar 28, 2024 |
| FY2022 | Sep 30, 2022 | (1) | Jun 12, 2023 |
| FY2022 | Jun 30, 2022 | (1) | Jun 12, 2023 |
| FY2022 | Dec 31, 2021 | (6) | Jun 12, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (13) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (7,478) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (79,782) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | (19) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (6) | Jun 12, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 854,371 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 1,370 | Mar 18, 2026 |
| FY2023 | Dec 31, 2023 | 825,459 | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | 491,345 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 905,685 | Jun 12, 2023 |